Abstract:Background: Lung tumors harboring genomic rearrangements involving ROS1 clinically benefits from crizotinib therapy. Our retrospective study aims to compare the efficacy of chemotherapy and crizotinib in the first-line setting and evaluate other clinical and molecular factors that might impact crizotinib efficacy in real-world practice. Methods: ROS1 rearrangements were retrospectively analyzed from NGS data of 21,747 treatment-naive patients diagnosed with lung cancer at various hospitals from 4 provinces of China. Treatment response and survival outcomes were analyzed in 235 patients with locally advanced to advanced disease who received first-line chemotherapy (n=67) or crizotinib (n=168). Findings: A total of 233 different ROS1 fusion partners were detected from 264 patients, with CD74 as the most common partner. The overall response rate was 85.7% (144/168) for front-line crizotinib and 41.8% (28/67) for chemotherapy. Patients treated with front-line crizotinib had significantly longer median progression-free survival (mPFS) than chemotherapy (18.0 months vs. 7.0 months, p<0.001). Patients harboring CD74-ROS1 fusion had significantly shorter mPFS with crizotinib than those harboring non-CD74-ROS1 fusions (17.0 months vs. 21.0 months; p=0.008). Baseline brain metastasis contributed to decreased efficacy of crizotinib (16.0 months vs. 22.0 months; p=0.02). The presence of CNS progression (n=61) with or without baseline CNS metastasis was associated with longer mPFS than those with non-CNS progression (n=48, 19.0 months vs. 11.5 months, p<0.001). Crizotinib as front-line therapy provided significantly longer mPFS than as second-line therapy (18.0 months vs. 11.0 months; p=0.028). The emergence of secondary ROS1 mutations mediated the crizotinib resistance of a majority of our cohort (54.8%, 23/42), particularly those with non-CNS metastasis at baseline (67.9%, 19/28; p=0.015). Interpretation: Our results demonstrate that patients with different ROS1 fusion variants have distinct clinical outcomes to crizotinib therapy due to baseline clinical and molecular factors that could affect the efficacy of crizotinib. Trial Registration: This study was also registered as a clinical trial (CORE, NCT03646994). Funding Statement: This work received financial support from the Natural Science Foundation of Hunan Province (2018RS3106, 2018SK50901, 2019-TJ-N04, 2019JJ50357, 2019SK4010, and 2020JJ3025), and CAS “Light of West China Program”. Declaration of Interests: Analyn Lizaso and Hao Liu declare that they are employees of Burning Rock Biotech. All the other authors declare no conflict of interest. Ethics Approval Statement: Approval was obtained from the Hunan Cancer Hospital Institutional Review Board Committee (2017YYQ-SSB-026).

Crizotinib Vs Platinum-Based Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with Different ROS1 Fusion Variants

Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Versus Chemotherapy As a First-Line Treatment

Antitumor Activity of First-Line Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancers: A Large Cohort, Multi-Center, Retrospective Study

First‐line Crizotinib Versus Platinum‐pemetrexed Chemotherapy in Patients with Advanced ROS1‐rearranged Non‐small‐cell Lung Cancer

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non–Small Cell Lung Cancer

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib Versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Final Overall Survival, Safety, and Quality of Life Results from a Phase 2 Study of Crizotinib in East Asian Patients with ROS1-Positive Advanced NSCLC

O3-4-1Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC)

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

[Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC].

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Impact of PD-L1 Expression on the Efficacy of First-Line Crizotinib in Advanced ROS1-rearranged NSCLC

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer.

First-Line Versus Second Or Further-Line Crizotinib For Trial Patients With Advanced Non-Small-Cell Lung Cancer Harboring Alk Rearrangements.

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma